These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 32904753)

  • 1. Gliosis Precedes Amyloid-β Deposition and Pathological Tau Accumulation in the Neuronal Cell Cycle Re-Entry Mouse Model of Alzheimer's Disease.
    Park KHJ; Barrett T
    J Alzheimers Dis Rep; 2020 Jul; 4(1):243-253. PubMed ID: 32904753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuronal Cell Cycle Re-Entry Enhances Neuropathological Features in AppNLF Knock-In Mice.
    Barrett T; Stangis KA; Saito T; Saido T; Park KHJ
    J Alzheimers Dis; 2021; 82(4):1683-1702. PubMed ID: 34219712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models.
    Sebastian Monasor L; Müller SA; Colombo AV; Tanrioever G; König J; Roth S; Liesz A; Berghofer A; Piechotta A; Prestel M; Saito T; Saido TC; Herms J; Willem M; Haass C; Lichtenthaler SF; Tahirovic S
    Elife; 2020 Jun; 9():. PubMed ID: 32510331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease.
    Streit WJ; Braak H; Xue QS; Bechmann I
    Acta Neuropathol; 2009 Oct; 118(4):475-85. PubMed ID: 19513731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.
    Schweig JE; Yao H; Beaulieu-Abdelahad D; Ait-Ghezala G; Mouzon B; Crawford F; Mullan M; Paris D
    Acta Neuropathol Commun; 2017 Sep; 5(1):69. PubMed ID: 28877763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical and morphological characterization of the AβPP/PS/tau triple transgenic mouse model and its relevance to sporadic Alzheimer's disease.
    Hunter JM; Bowers WJ; Maarouf CL; Mastrangelo MA; Daugs ID; Kokjohn TA; Kalback WM; Luehrs DC; Valla J; Beach TG; Roher AE
    J Alzheimers Dis; 2011; 27(2):361-76. PubMed ID: 21860086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
    Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
    Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of cell cycle proteins in transgenic mice in response to neuronal loss but not amyloid-beta and tau pathology.
    Lopes JP; Blurton-Jones M; Yamasaki TR; Agostinho P; LaFerla FM
    J Alzheimers Dis; 2009; 16(3):541-9. PubMed ID: 19276549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer's and other CNS pathologies.
    Ji B; Maeda J; Sawada M; Ono M; Okauchi T; Inaji M; Zhang MR; Suzuki K; Ando K; Staufenbiel M; Trojanowski JQ; Lee VM; Higuchi M; Suhara T
    J Neurosci; 2008 Nov; 28(47):12255-67. PubMed ID: 19020019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prodromal neuroinflammatory, cholinergic and metabolite dysfunction detected by PET and MRS in the TgF344-AD transgenic rat model of AD: a collaborative multi-modal study.
    Chaney AM; Lopez-Picon FR; Serrière S; Wang R; Bochicchio D; Webb SD; Vandesquille M; Harte MK; Georgiadou C; Lawrence C; Busson J; Vercouillie J; Tauber C; Buron F; Routier S; Reekie T; Snellman A; Kassiou M; Rokka J; Davies KE; Rinne JO; Salih DA; Edwards FA; Orton LD; Williams SR; Chalon S; Boutin H
    Theranostics; 2021; 11(14):6644-6667. PubMed ID: 34093845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models.
    Natunen T; Takalo M; Kemppainen S; Leskelä S; Marttinen M; Kurkinen KMA; Pursiheimo JP; Sarajärvi T; Viswanathan J; Gabbouj S; Solje E; Tahvanainen E; Pirttimäki T; Kurki M; Paananen J; Rauramaa T; Miettinen P; Mäkinen P; Leinonen V; Soininen H; Airenne K; Tanzi RE; Tanila H; Haapasalo A; Hiltunen M
    Neurobiol Dis; 2016 Jan; 85():187-205. PubMed ID: 26563932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct microglial response against Alzheimer's amyloid and tau pathologies characterized by P2Y12 receptor.
    Maeda J; Minamihisamatsu T; Shimojo M; Zhou X; Ono M; Matsuba Y; Ji B; Ishii H; Ogawa M; Akatsu H; Kaneda D; Hashizume Y; Robinson JL; Lee VM; Saito T; Saido TC; Trojanowski JQ; Zhang MR; Suhara T; Higuchi M; Sahara N
    Brain Commun; 2021; 3(1):fcab011. PubMed ID: 33644757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amyloid β Protein Aggravates Neuronal Senescence and Cognitive Deficits in 5XFAD Mouse Model of Alzheimer's Disease.
    Wei Z; Chen XC; Song Y; Pan XD; Dai XM; Zhang J; Cui XL; Wu XL; Zhu YG
    Chin Med J (Engl); 2016 Aug; 129(15):1835-44. PubMed ID: 27453234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct chronology of neuronal cell cycle re-entry and tau pathology in the 3xTg-AD mouse model and Alzheimer's disease patients.
    Hradek AC; Lee HP; Siedlak SL; Torres SL; Jung W; Han AH; Lee HG
    J Alzheimers Dis; 2015; 43(1):57-65. PubMed ID: 25061053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TLR4 mutation reduces microglial activation, increases Aβ deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease.
    Song M; Jin J; Lim JE; Kou J; Pattanayak A; Rehman JA; Kim HD; Tahara K; Lalonde R; Fukuchi K
    J Neuroinflammation; 2011 Aug; 8():92. PubMed ID: 21827663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A1 reactive astrocytes and a loss of TREM2 are associated with an early stage of pathology in a mouse model of cerebral amyloid angiopathy.
    Taylor X; Cisternas P; You Y; You Y; Xiang S; Marambio Y; Zhang J; Vidal R; Lasagna-Reeves CA
    J Neuroinflammation; 2020 Jul; 17(1):223. PubMed ID: 32711525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibiting TLR2 activation attenuates amyloid accumulation and glial activation in a mouse model of Alzheimer's disease.
    McDonald CL; Hennessy E; Rubio-Araiz A; Keogh B; McCormack W; McGuirk P; Reilly M; Lynch MA
    Brain Behav Immun; 2016 Nov; 58():191-200. PubMed ID: 27422717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease.
    Mori T; Koyama N; Arendash GW; Horikoshi-Sakuraba Y; Tan J; Town T
    Glia; 2010 Feb; 58(3):300-14. PubMed ID: 19705461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GFAP and vimentin deficiency alters gene expression in astrocytes and microglia in wild-type mice and changes the transcriptional response of reactive glia in mouse model for Alzheimer's disease.
    Kamphuis W; Kooijman L; Orre M; Stassen O; Pekny M; Hol EM
    Glia; 2015 Jun; 63(6):1036-56. PubMed ID: 25731615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tau accumulation in the retina promotes early neuronal dysfunction and precedes brain pathology in a mouse model of Alzheimer's disease.
    Chiasseu M; Alarcon-Martinez L; Belforte N; Quintero H; Dotigny F; Destroismaisons L; Vande Velde C; Panayi F; Louis C; Di Polo A
    Mol Neurodegener; 2017 Aug; 12(1):58. PubMed ID: 28774322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.